{"filings":[{"id":109764,"accession_number":"0001193125-26-109472","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Longevity Health appoints new CEO, closes $200K investment from new chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ram Ajjarapu appointed Chairman and CEO effective March 16, 2026; invested $200K via private placement of 689,656 shares at $0.29.","Rajiv Shukla resigned as CEO and Chairman; separation includes 12 months of $30K/month severance plus $480K bonus upon $1M capital raise.","Company intends to use proceeds for working capital and pursue acquisition-focused growth strategy.","Shares issued in unregistered private placement; resale registration statement to be filed within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126296,"accession_number":"0001193125-25-317638","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Longevity Health terminates merger agreement with True Health after Nov 30 deadline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Company provided termination notice on Dec 8, 2025; merger not consummated by Nov 30, 2025.","No termination fee payable by either party under Merger Agreement.","Deal originally signed July 14, 2025; amended Nov 3, 2025; failed to close by deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126295,"accession_number":"0001193125-25-272538","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Longevity Health amends merger terms with True Health; sets $3 cap on exchange price","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger Shares capped at $59M divided by lesser of 15-day VWAP and $3.00, reducing potential dilution if stock exceeds $3.","Earnout Shares capped at $20M divided by lesser of 15-day VWAP and $3.00, with same price floor.","Amendment executed Nov 3, 2025, altering original July 14, 2025 Agreement; all other terms unchanged.","Merger consideration now linked to Parent Market Price: volume-weighted average closing price over 15 days pre-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143047,"accession_number":"0000950170-25-114421","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Longevity Health delisted from Nasdaq, now trades on OTC; merger with True Health planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received delisting notice from Nasdaq on Sept 10, 2025 for failure to cure Listing Rule 5550(b)(2) deficiency.","Securities delisted at open Sept 12, 2025; common stock and warrants began trading on OTC Markets.","Company states operations unaffected; will continue periodic SEC filings.","Intends to pursue previously disclosed merger with True Health Inc. and relist on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143046,"accession_number":"0000950170-25-095608","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","5.01","8.01","9.01"],"status":"ready","headline":"Longevity Health to merge with THPlasma in $59M all-stock deal; Biolabs terminated","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger values THPlasma at $59M plus $20M earnout; Longevity shares at $3.00 (12% premium to July 11 close).","THPlasma has 5 plasma centers; FY2025E revenue $10M, EBITDA $2M; FY2026E revenue $32M, EBITDA $7M.","Post-closing (Q4 2025), Rajiv Shukla becomes Executive Chairman; George Chi becomes Co-Chairman & CEO.","Prior merger with 20/20 Biolabs automatically terminated July 8, 2025; no termination fees.","No cash condition precedent; approved by both boards, subject to stockholder and Nasdaq approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161157,"accession_number":"0000950170-25-090015","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Longevity Health extends merger deadline with 20/20 Biolabs to July 8, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Due Diligence Contingency Deadline moved to July 8, 2025; merger agreement will auto-terminate on that date unless extended in writing.","Amendment signed June 24, 2025; original Agreement and Plan of Merger dated April 11, 2025.","No other provisions of the merger agreement were modified beyond the deadline extension.","Parties: Longevity Health Holdings, Merger Sub, 20/20 Biolabs, and stockholder representative Jonathan Cohen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161156,"accession_number":"0000950170-25-077905","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Longevity Health raises ~$1.96M via ATM sale of 479,621 shares at $4.08","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 479,621 shares of common stock at average $4.08/share, gross proceeds ~$1.96M before fees.","Cash runway extended into Q1 FY26 based on pro forma FY24 sales, excluding planned 20/20 merger.","CEO cites continued investor confidence as company advances merger with 20/20 Biolabs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161155,"accession_number":"0000950170-25-075865","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nasdaq panel grants conditional continued listing for Longevity Health pending merger with 20/20 Biolabs by Sept 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel granted continued listing condition: complete merger with 20/20 Biolabs and meet initial listing rules by Sept 2, 2025.","Company filed S-4 for merger on May 8, 2025, and effected 1-for-30 reverse stock split on May 12, 2025.","Panel based decision on review of financial statements and pro forma projections of combined company.","Chairman/CEO Rajiv Shukla stated focus on completing merger to satisfy Nasdaq requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161154,"accession_number":"0000950170-25-072931","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Longevity Health Q1 pro forma sales $663k, merger with 20/20 BioLabs progressing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XAGE Q1 unaudited pro forma sales ~$663k (+8% YoY); 20/20 sales ~$562k (+15% YoY).","Merger agreement with 20/20 signed April 11; S-4 filed May 8; closing subject to conditions.","1-for-30 reverse stock split completed May 12; trading at split-adjusted price from May 14.","Expected Q2 launches: XAGE medicated cleanser, 20/20 inflammatory biomarker test, and OneTest pilot with Giant Food.","Company evaluating options for additional financing, anticipates primary investment in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161153,"accession_number":"0000950170-25-068578","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Longevity Health Holdings executes 1-for-30 reverse stock split effective May 12, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1-for-30, effective 9:00 a.m. ET on May 12, 2025.","Shares reduced from ~30.1M to ~1M; no fractional shares issued (rounded up).","Common stock to trade split-adjusted on Nasdaq starting May 14, 2025 under ticker XAGE.","CUSIP changed to 142922129 for common stock; warrants CUSIP unchanged.","Proportional adjustments made to outstanding options, warrants, and equity plan shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161152,"accession_number":"0000950170-25-053506","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","5.01","8.01","9.01"],"status":"ready","headline":"Longevity Health signs merger with 20/20 Biolabs; combined co. valued ~$99M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-stock merger: 20/20 stockholders to own ~50.1% of combined co. (pre-concurrent financing).","Combined co. FY2025 revenue forecast to double to ~$7-8M from ~$3-4M; ~$1M synergies expected.","Post-closing: Jonathan Cohen (20/20 CEO) becomes CEO; Rajiv Shukla remains Chairman.","Concurrent financing to raise min. $4M gross proceeds; also at-market offering for up to $2M common stock.","Closing expected Q3 2025; subject to stockholder approvals, Nasdaq listing, and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161151,"accession_number":"0000950170-25-049943","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Longevity Health receives Nasdaq delisting notice for bid-price deficiency; hearing April 15","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to regain $1.00 minimum bid price by March 31, 2025 compliance deadline.","Nasdaq Determination Letter (April 1) adds bid-price deficiency as additional delisting basis.","Deficiency will be considered at April 15 hearing alongside existing MVLS shortfall.","Company intends to seek extension from Nasdaq Hearings Panel; no assurance of success.","Tickers XAGE (common) and XAGEW (warrants) at risk of delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179317,"accession_number":"0000950170-25-047788","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K/A","filed_at":"2025-03-31T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Longevity Health acquires skincare business with $2M net loss and going concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired skincare business from PMGC Holdings for undisclosed value; sale closed Jan 16, 2025.","Nine-month revenue $1.75M, gross profit $1.28M, net loss $2.01M.","Operating cash flow negative $2.24M; working capital only $249K.","Audited 2023 and unaudited 2024 financials filed; going concern warning issued by management.","Net investment by parent $402K; business funded by parent contributions of $2.25M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179320,"accession_number":"0000950170-25-045392","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve reverse stock split and warrant issuance at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 2 (reverse split 1:15 to 1:30) passed: 18.5M for, 0.55M against, no broker non-votes.","Proposal 1 (warrant issuance >20% of outstanding) passed: 14.7M for, 178k against, 3.9M broker non-votes.","Proposal 3 (adjournment) not needed; 63% quorum achieved on March 24, 2025.","Reverse split ratio to be set by Board at discretion; no effective date announced.","Warrants relate to Dec 23, 2024 Securities Purchase Agreement; exercise triggers dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179319,"accession_number":"0000950170-25-035950","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Carmell rebrands to Longevity Health (XAGE); guides FY25 rev $3-4M; names Vice Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to Longevity Health Holdings effective March 5; tickers to XAGE/XAGEW March 10.","Patrick Sturgeon appointed Vice Chairman; previously CFO and board director since July 2023.","Combined sales grew 34% in Jan-Feb 2025 vs 2024 post Elevai acquisition.","Elevai's post-acquisition burn rate reduced >50% via overhead cost synergies.","FY25 revenue guidance $3-4M; Q2 2025 product launches include hair growth serum, soapless facial cleanser, etc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179318,"accession_number":"0000950170-25-033793","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carmell receives Nasdaq delisting notice for failing MVLS minimum; plans appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Failed to regain $35M MVLS compliance by Feb 26, 2025 deadline; notice received March 4.","Must appeal by March 11, 2025 or trading suspended on March 13; Form 25-NSE to follow.","Company intends to appeal but cautions no guarantee of success for continued listing.","Redeemable warrants (CTCXW) also subject to delisting along with common stock (CTCX)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179316,"accession_number":"0000950170-25-008865","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Kendra Bracken-Ferguson departs; Executive Chairman Rajiv Shukla appointed CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kendra Bracken-Ferguson and Carmell mutually agreed to end her CEO role effective January 20, 2025.","She will receive $150,000 in six equal monthly installments under a separation and release agreement.","Rajiv Shukla, current Executive Chairman, appointed CEO effective January 24, 2025; he previously served as CEO until July 2024.","Shukla will continue in his role as Executive Chairman.","No arrangement or understanding with any other person, and no family relationships with officers or directors disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179315,"accession_number":"0000950170-25-006024","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["2.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell closes acquisition of Elevai Skincare; issues ~1.15M shares, $2.5M revenue portfolio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase consideration: ~1.1M shares of Carmell common at $0.8488/sh, plus 117,814 holdback shares for 12-month indemnification.","Earnout: 5% of annual net sales from existing products for 5 years; $500k milestone if hair/scalp products reach $500k revenue within 24 months.","Acquired assets include product portfolio with FY2024 revenue ~$2.5M, inventory ~$1.0M, and accounts receivable ~$0.03M.","Post-closing Carmell common shares outstanding ~30.1M; Chairman expects synergies, expanded portfolio, and improved cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179314,"accession_number":"0000950170-25-001359","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell to acquire Elevai Skincare assets for ~$1.1M stock, earnout, and assumption of liabilities","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price includes ~$1.1M in Carmell common stock (with $100K escrow), ~$57K cash on inventory sale, 5% net sales earnout for 5 years, and $500K milestone.","Assets include product portfolio with trailing 12-month revenue of ~$2.5M, ~$1.0M inventory, commercial team, and accounts receivable.","Acquisition expected to close by January 17, 2025, subject to customary closing conditions.","Carmell to issue unregistered shares as closing stock consideration with registration rights within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195996,"accession_number":"0000950170-24-141623","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-12-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Carmell raises $1.85M in private placement of stock and warrants at $0.23/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 8,065,210 shares and equal 5-year warrants at $0.23 each; gross proceeds $1.85M.","Warrants exercisable after stockholder approval; potential additional $1.85M if exercised.","Closing expected Jan 2, 2025; proceeds for commercial team build-out and general purposes.","Post-closing shares outstanding approx. 29M; priced at slight premium to Dec 23 close.","Brookline Capital Markets acted as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195995,"accession_number":"0000950170-24-129329","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Carmell furnishes investor presentation for meetings; specific content unavailable in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1 for investor meetings on or after Nov 20, 2024.","Exhibit text is cut off; only title and partial cautionary statement visible.","No financial results, product updates, or other concrete data extractable from excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195994,"accession_number":"0000950170-24-112392","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carmell receives Nasdaq deficiency notice for bid price below $1; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Carmell on Sept 30, 2024 that its common stock failed to maintain minimum $1 bid price for 31 consecutive business days.","Company has until March 31, 2025 to regain compliance; closing bid price must be $1 for at least 10 consecutive days.","If not cured, Nasdaq may grant an additional 180-day period if other listing standards are met.","No immediate impact on trading of common stock (CTCX) or warrants (CTCXW); company evaluating options.","There is no assurance that Carmell will be able to regain compliance with the Minimum Bid Price Requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212262,"accession_number":"0000950170-24-102375","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Carmell receives Nasdaq MVLS deficiency notice; must regain $35M minimum by Feb 26, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MVLS fell below $35M minimum from July 15 to Aug 29, 2024.","Nasdaq gave 180 days (until Feb 26, 2025) to regain compliance.","Compliance requires MVLS ≥ $35M for 10 consecutive business days.","Failure may lead to delisting; Company reviewing options.","Trading of CTCX and CTCXW continues for now."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212261,"accession_number":"0000950170-24-087128","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Carmell appoints Kendra Bracken-Ferguson as CEO; Rajiv Shukla becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajiv Shukla resigned as CEO July 29, 2024; he remains Executive Chairman.","Kendra Bracken-Ferguson appointed CEO effective July 30, 2024; salary $300k, bonus target 50%, options $700k.","New CEO has 20+ years beauty/wellness experience; founded BrainTrust, co-founded Digital Brand Architects.","Carmell added to Russell Microcap Index, reduced cash burn 50%, raised $3M, began commercial sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212260,"accession_number":"0000950170-24-084333","cik":1842939,"company_name":"Longevity Health Holdings, Inc.","ticker":"XAGE","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Carmell Corp shareholders elect Richard Upton director, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Richard Upton elected Class I director with 9,525,320 votes for, 24,465 withheld, 1,921,908 broker non-votes.","Adeptus Partners, LLC ratified as independent auditor for FY 2024 with 11,455,591 for, 12,663 against, 3,439 abstain.","Quorum of 11,471,693 shares (56% of outstanding) present at July 12, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":790000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}